PX-866 **

产品名称：PX-866
产品货号：LC  P-7501
产品规格：10 MG
PX-866, a derivative of wortmannin, potently inhibited purified phosphoinositide (PtdIns)-3-kinase (IC50 = 0.1 nM) and PtdIns-3-kinase signaling (IC50 = 20 nM) as assessed by phospho-Ser473-Akt levels in HT-29 colon cancer cells.  PX-866 showed antitumor activity in vivo against s.c. A-549 human lung cancer xenografts and OvCar-3 human ovarian cancer in immunodeficient mice.  PX-866 also enhanced the antitumor activity of cisplatin against A-549 xenografts and radiation treatment against OvCar-3 xenografts.  Ihle, N.T., et al.  "Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling."  Mol. Cancer Ther. 3:  763-772 (2004).
PX-866 appears to inhibit tumor growth by blocking the phosphatidylinositol 3-kinase (PI3K) pathway and cell motility.  Howes, A.L., et al.  "The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures."  Mol. Cancer Ther. 6:  2505-2514 (2007).
Hyperglycemia is a side effect of PX-866 treatment.  Combination treatment of peroxisome proliferator-activated receptor γ agonist pioglitazone with PX-688 can overcome the increase in blood glucose without affecting antitumor activity caused by PX-866.  Ihle, N.T., et al.  "Peroxisome proliferator-activated receptor gamma agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting antitumor activity."  Mol. Cancer Ther. 8:  94-100 (2009).
PX-866 is a PI3-K inhibitor with selectivity for p110α. It enhanced the antitumor activity of gefitinib against A-549 non-small cell lung cancer (NSCLC) xenografts, giving complete tumor growth control during the early stages of treatment.  Ihle, N.T., et al.  "The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts."  Mol. Cancer Ther. 4:  1349-1357 (2005).
STRUCTURE NOTE:  Chemical Abstracts Service defines PX-866 as having the "E" configuration for the enamine double bond at the lower left corner of the structure.  At least one other vendor's structure for PX-866 has the incorrect "Z" configuration for that double bond.
Storage:  Store at or below -20 ºC.  Solubility:  Soluble in DMSO at 200 mg/mL; soluble in ethanol at 200 mg/mL; very poorly soluble in water; maximum solubility in plain water is estimated to be about 10-20 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility.  Disposal:  A

产品留言

标题

联系人

联系电话

内容

验证码

点击换一张

注：1.可以使用快捷键Alt+S或Ctrl+Enter发送信息!
2.如有必要,请您留下您的详细联系方式!